Sonoma Pharmaceuticals, Inc. (SNOA) Stock

Sonoma Pharmaceuticals, Inc. (SNOA) is a Healthcare stock trading at $1.35 (as of 2026-08-20), with a market capitalization of $2.34M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sonoma Pharmaceuticals, Inc. develops and manufactures stabilized hypochlorous acid (HOCl) products used in wound care, animal health, eye care, oral care, and dermatological conditions. Its product lines include prescription and non-prescription HOCl therapies such as Epicyn, Levicyn, Celacyn, SebuDerm, Acuicyn, and Microcyn for use by customers in the United States, Latin America, Europe, and other international markets.

Understand Sonoma Pharmaceuticals, Inc.: how it makes money

Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid (HOCl) products for wound care, skin conditions, and other care areas, selling prescription and non-prescription products such as Epicyn, Levicyn, Celacyn gel, and SebuDer.

The companys profit model is driven by sales of its HOCl product portfolio (Epicyn, Levicyn, Celacyn gel, and SebuDer) across its targeted care areas and markets.

Business quality (Weak): Limited company-specific detail is provided, with no reportable segments or operating KPIs in the dataset, so the analysis relies mainly on the product description and the provided gross and operating margin figures.

Bull case

  • Product portfolio across multiple indications: The company offers HOCl products across wound care, eye care, oral care, animal health care, and dermatological conditions, including Epicyn, Levicyn, Celacyn gel, and SebuDer.
  • Positive gross margin in the provided period: For the 2025-12-31 period, gross margin is 37.9%, indicating the company can generate a positive gross profit from its products in the provided data.

Bear case

  • Operating losses in the provided period: For the 2025-12-31 period, operating margin is -15.6%, meaning operations were loss-making based on the provided figures.
  • No operating KPIs provided to track demand and execution: The dataset includes no operating metrics candidates (for example, prescriptions, units, or other engagement measures), which makes it harder to monitor the key drivers behind performance.
Valuation — source: SEC EDGAR (first-party)
Price$1.35
Market Cap$2.34M
Price / Book0.35
Price / Sales0.11
FCF Yield-390.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$19.53M
Net Margin-16.3%
Return on Equity-34.3%
Debt / Equity0.02
Current Ratio2.99
Revenue Growth (YoY)36.7%
EPS Growth (YoY)-32.3%
FCF Growth (YoY)2355.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-18.36 (distress)
Piotroski F-Score3/9 (weak)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($68749.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOAmy Trombly
Employees10
CountryUS
IPO Date2007-01-25

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Intelligent Bio Solutions Inc. (INBS)
  • enVVeno Medical Corporation (NVNO)
  • Picard Medical, Inc. (PMI)
  • Autonomix Medical, Inc. Common Stock (AMIX)
  • Bluejay Diagnostics, Inc. (BJDX)
  • Catheter Precision, Inc. (VTAK)
  • Amundi Core MSCI Emerging Markets UCITS ETF EUR Dist (AEMD)
  • INVO Fertility, Inc. (IVF)
SNOA earnings history · SNOA institutional & insider holders · SNOA KPIs & operating metrics · SNOA financials · SNOA investor presentations & press releases · SNOA SEC filings · SNOA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.